Advertisement
Australia markets close in 3 hours 16 minutes
  • ALL ORDS

    7,976.10
    -26.40 (-0.33%)
     
  • ASX 200

    7,724.80
    -24.90 (-0.32%)
     
  • AUD/USD

    0.6638
    +0.0000 (+0.01%)
     
  • OIL

    78.20
    -0.42 (-0.53%)
     
  • GOLD

    2,321.00
    +3.00 (+0.13%)
     
  • Bitcoin AUD

    100,744.50
    -1,414.74 (-1.38%)
     
  • CMC Crypto 200

    1,420.72
    +7.76 (+0.55%)
     
  • AUD/EUR

    0.6176
    +0.0004 (+0.06%)
     
  • AUD/NZD

    1.0776
    +0.0023 (+0.22%)
     
  • NZX 50

    11,853.98
    -18.66 (-0.16%)
     
  • NASDAQ

    19,576.92
    +111.74 (+0.57%)
     
  • FTSE

    8,163.67
    -51.81 (-0.63%)
     
  • Dow Jones

    38,647.10
    -65.11 (-0.17%)
     
  • DAX

    18,265.68
    -365.18 (-1.96%)
     
  • Hang Seng

    17,970.51
    -142.12 (-0.78%)
     
  • NIKKEI 225

    38,709.02
    -11.45 (-0.03%)
     

Better Long-Term Buy: AbbVie or Novo Nordisk?

Better Long-Term Buy: AbbVie or Novo Nordisk?

Pharmaceutical companies Novo Nordisk (NYSE: NVO) and AbbVie (NYSE: ABBV) seem to be headed in separate directions. Denmark-based Novo Nordisk, thanks to growing sales of diabetes drug Ozempic and obesity therapy Wegovy, is predicting sales to grow between 24% to 30% and operating profit to rise 28% to 34% this year. AbbVie, on the other hand, thanks to the loss of patent protection for immunology blockbuster Humira, has forecasted 2023 adjusted earnings per share (EPS) to drop by 20% to 23%, from 2022 levels.